ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
ProQR Therapeutics NV PRQR
$1.65
▲ +0.00%
(+$0.00)
⬆️ Above Yest. High
Open
$1.66
Prev Close
$1.65
Day Range
$1.63 – $1.70
52W Range
$1.33 – $3.10
Market Cap
$227.84M
Beta
0.22
EPS (TTM)
$-0.40
📋 Company Profile
| Industry | Biotechnology |
| Country | NL |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | EUR |
| IPO Date | 2014-09-18 |
| Shares Out. | 132,990,000 |
| Website | proqr.com/ ↗ |
| Phone | 31881667000 |
| Employees | 187 |
| Total Assets | $132.3M |
| Total Liabilities | $74.4M |
| Equity | $57.9M |
About ProQR Therapeutics NV
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
ProQR Therapeutics NV is a publicly traded company under the ticker symbol PRQR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)